Get A Drip Taps Medical Chief as Longevity Market Booms Amid Scrutiny

LONDON, UK – June 12, 2026 – Get A Drip, a high-street chain at the forefront of the UK’s booming longevity market, has appointed Dr Luke Pratsides as its new Chief Medical Officer. The move signals a push for greater clinical authority within a company capitalizing on a dramatic consumer shift towards proactive health, a sector projected by analysts to be worth over $31 billion globally this year.

Dr Pratsides’ appointment comes as the company, and the wider wellness industry, navigates the complex intersection of surging consumer demand, evolving scientific evidence, and increasing regulatory oversight. As treatments once confined to exclusive clinics become mainstream, Get A Drip is positioning itself to lead the charge, but the path forward involves balancing commercial ambition with clinical responsibility.

The High Street's Longevity Gold Rush

The public's appetite for a longer, healthier life has never been more palpable. While Get A Drip’s press release highlights a tripling of global Google searches for “longevity” in the past year, verifiable data shows a clear and sustained surge in related queries for specific interventions like NMN supplements. This groundswell of interest is translating directly into revenue. Get A Drip reports a staggering 772.4% increase in bookings for its NAD+ treatments—a molecule central to cellular metabolism—between 2023 and 2025.

This explosive growth is the realization of the vision held by founder and CEO Richard Chambers, who started the company in 2017 after IV nutrition therapy proved life-changing during his battle with complications from Type 1 diabetes. From a single clinic in London's Shoreditch, the company has expanded to over 30 locations, built on a mission to democratize access to preventative health technologies.

“Healthcare is at a pivotal juncture,” says Chambers. “Treatments that were once seen as a luxury are now featured as part of everyday wellness routines. As technology evolves and science continues to support the benefits, we're seeing a step change in consumer behaviour.” This change has fueled the company’s aggressive expansion, with plans to operate over 100 clinics globally in the coming years through a franchise model.

A New Clinical Guard for a New Era

To navigate this new era, the company has brought in Dr Luke Pratsides, a physician whose career bridges the gap between public and private healthcare. With experience as a frontline NHS doctor and, more recently, as the medical lead at the men’s health tech company Numan, Dr Pratsides brings a crucial perspective on clinical governance and innovation.

At Numan, he was instrumental in building the company’s prescribing services for GLP-1 weight-loss medications and testosterone hormone therapy, two areas that require rigorous clinical oversight. His appointment suggests Get A Drip is preparing for a future where its offerings are more deeply integrated with established medical protocols. Dr Pratsides himself emphasizes the goal is not just a longer life, but a better one, stating it's important to realize that longevity is “not just increasing years of life, but increasing the years of healthy life.”

For Get A Drip, his role will be to spearhead what Chambers calls “progressive, proactive longevity measures.” This means steering the company’s innovation pipeline, which already includes a broad menu of services from IV drips and blood diagnostics to cryotherapy chambers and hyperbaric oxygen therapy (HBOT).

Science, Hype, and the Search for Healthspan

While consumer enthusiasm is high, the scientific foundations for many popular longevity treatments remain a subject of intense debate, a key challenge Dr Pratsides will face. IV nutrition therapy, the company's foundational service, is a prime example. While indispensable in hospital settings, its use for general 'wellness' has drawn criticism. NHS England has previously issued warnings about companies “peddling fake health remedies,” and there is limited high-quality clinical evidence to support broad claims of enhanced energy or immunity in healthy individuals.

Similarly, NAD+ treatments, a major growth driver for the company, exist in a grey area. Research in animal models has shown promising results in reversing aspects of cellular aging. However, leading experts in the field caution that these supplements are not proven “longevity drugs” in humans, and NAD+ infusions are not approved by the FDA for anti-aging purposes.

Other advanced technologies offered, like Hyperbaric Oxygen Therapy, have shown intriguing potential in small-scale studies to increase telomere length—a key biomarker of aging—but researchers agree that large-scale trials are needed to validate these findings. Perhaps the most medically grounded of its newer offerings are the GLP-1 medications, which are proven for diabetes and weight management. While emerging research is exploring their potential role in healthy aging, the science is still in its infancy.

The Business of Bio-Hacking and Regulatory Realities

Get A Drip's success lies in its business model: making these cutting-edge treatments accessible and affordable. However, as the industry has grown from a niche market into a high-street phenomenon, so has the attention of regulators. In a landmark move in 2022, the UK’s Care Quality Commission (CQC) made it mandatory for all providers offering intravenous therapies to be registered, a move designed to enforce safety standards and professionalize the sector. Get A Drip’s CQC registration is now a critical license to operate, not just a marketing advantage.

This push for legitimacy is vital as the company scales. While in-clinic service is often highly rated by customers, the operational challenges of rapid growth are apparent in mixed online reviews for its e-commerce and pharmacy services, which cite issues with communication and delivery. Maintaining quality control and clinical integrity across a sprawling franchise network will be a primary test for the new leadership.

Dr Pratsides’ focus appears to be on grounding the company’s ambitious goals in established preventative medicine. “As a longevity organisation, we are focused on reducing risk across four major areas: cancer, cardiovascular disease, metabolic disease and neurodegenerative conditions,” he states. His closing sentiment encapsulates the industry's current state of play: “We may not have all the answers, but we have powerful tools in modern preventative medicine to move the needle.”